10-Q: Corcept Therapeutics Reports Mixed Q2 2025 Results Amid Strong Pipeline Progress and Rising Expenses

Corcept Therapeutics reported increased product revenue driven by higher sales volume but experienced a decline in net income due to significantly higher operating expenses, while advancing key drug candidates with positive clinical trial results and new FDA submissions.

Summary

• Product revenue, net, increased to $351.6 million for the six months ended June 30, 2025, up from $310.6 million in the comparable 2024 period, driven by a 49.0% increase in sales volume, partially offset by a 17.3% decrease in average price due to the authorized generic version of Korlym.
• Net income decreased to $55.7 million for the six months ended June 30, 2025, compared to $63.3 million in the comparable 2024 period.
• Income from operations decreased significantly to $30.1 million for the six months ended June 30, 2025, down from $65.1 million in the comparable 2024 period.
• Total operating expenses rose to $321.6 million for the six months ended June 30, 2025, from $245.5 million in the comparable 2024 period, primarily due to increased selling, general and administrative expenses.
• Selling, general and administrative expenses increased by 57.9% to $194.5 million for the six months ended June 30, 2025, compared to $123.2 million in the comparable 2024 period, driven by higher employee compensation and sales and marketing activities.
• Research and development expenses increased slightly to $121.2 million for the six months ended June 30, 2025, from $117.3 million in the comparable 2024 period, due to increased employee compensation and advancement of development programs.
• The company reported an income tax benefit of $14.4 million for the six months ended June 30, 2025, a significant shift from an income tax expense of $13.3 million in the comparable 2024 period, primarily due to increased stock compensation deductions and decreased pre-tax income.
• Cash, cash equivalents, and marketable securities totaled $515.0 million as of June 30, 2025, down from $603.2 million as of December 31, 2024.
• Net cash used in financing activities was $142.7 million for the six months ended June 30, 2025, largely due to $130.5 million in common stock repurchases under the Stock Repurchase Program.
• A New Drug Application (NDA) for relacorilant as a treatment for endogenous hypercortisolism was submitted to the FDA in December 2024 and accepted in March 2025, with a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025.
• An NDA for relacorilant plus nab-paclitaxel as a treatment for platinum-resistant ovarian cancer was submitted to the FDA in July 2025, based on positive Phase 3 ROSELLA and Phase 2 trial results.
• The Phase 3 ROSELLA trial for ovarian cancer met its Progression-Free Survival (PFS) endpoint, showing a 30% reduction in risk of disease progression (hazard ratio: 0.70; p-value: 0.008), and an interim analysis showed a 31% reduction in risk of death (hazard ratio: 0.69; p-value: 0.012).
• The Phase 2 DAZALS trial for ALS did not meet its primary endpoint, but an exploratory analysis found an 84% reduction in risk of death at the one-year mark for patients receiving 300 mg of dazucorilant (hazard ratio: 0.16; p-value: 0.0009).
• The MOMENTUM trial for hypercortisolism in patients with resistant hypertension was initiated in March 2025, with a planned enrollment of 1,000 patients.
• The MONARCH Phase 2b trial for MASH, initiated in October 2023, has closed screening for Cohort A and completed enrollment for Cohort B.

Sentiment

Score: 6

Explanation: The company demonstrates strong clinical pipeline progress with multiple NDA submissions and positive trial results, particularly for relacorilant in hypercortisolism and ovarian cancer, and an intriguing survival signal in ALS. Product revenue growth is also robust. However, these positives are significantly offset by a notable decline in net income and operating profit, driven by a substantial increase in selling, general, and administrative expenses. The aggressive share repurchase program is drawing down cash reserves. Furthermore, ongoing legal challenges and the anticipated negative impact of new government regulations (IRA, OBBBA) on future profitability introduce considerable uncertainty and risk.

Positives

• Product revenue increased by 13.2% year-over-year for the six months ended June 30, 2025, driven by a substantial 49.0% increase in sales volume.
• The CATALYST study for Korlym in patients with difficult-to-control diabetes met its primary endpoint, showing a clinically meaningful and statistically significant decrease in HbA1c of 1.47% (p-value: < 0.0001).
• Relacorilant's NDA for endogenous hypercortisolism was accepted by the FDA, with a PDUFA target action date of December 30, 2025, indicating significant progress towards market approval.
• The pivotal GRACE trial for relacorilant demonstrated clinically meaningful and statistically significant improvements in hypertension, hyperglycemia, weight, and body composition in hypercortisolism patients.
• Relacorilant's NDA for platinum-resistant ovarian cancer was submitted to the FDA in July 2025, supported by positive Phase 3 ROSELLA and Phase 2 trial results.
• The ROSELLA trial for ovarian cancer met its primary PFS endpoint, showing a statistically significant 30% reduction in disease progression risk, and an interim analysis indicated a meaningful 31% reduction in the risk of death.
• Relacorilant was well-tolerated in all trials, with no instances of hypokalemia, endometrial hypertrophy, drug-induced vaginal bleeding, adrenal insufficiency, or QT prolongation, which are serious adverse events associated with other treatments.
• Dazucorilant, despite missing its primary endpoint in the DAZALS trial for ALS, showed a statistically significant 84% reduction in the risk of early death in an exploratory analysis for the 300 mg dose.
• Miricorilant's Phase 1b trial for MASH identified a dosing regimen that reduced liver fat and improved liver health, leading to the initiation of the Phase 2b MONARCH trial.
• The company recorded an income tax benefit of $14.4 million for the six months ended June 30, 2025, compared to an expense in the prior year, partially offsetting the decline in pre-tax income.

Negatives

• Net income decreased by 11.9% for the six months ended June 30, 2025, compared to the prior year, despite increased product revenue.
• Income from operations decreased by 53.8% for the six months ended June 30, 2025, indicating a significant reduction in operational profitability.
• Total operating expenses increased by 31.0% for the six months ended June 30, 2025, primarily driven by a substantial increase in selling, general and administrative expenses.
• Selling, general and administrative expenses increased by 57.9% for the six months ended June 30, 2025, reflecting higher employee compensation and sales and marketing activities.
• Cash, cash equivalents, and marketable securities decreased by $88.2 million from December 31, 2024, to June 30, 2025, partly due to significant share repurchases.
• Net cash provided by operating activities decreased to $49.1 million for the six months ended June 30, 2025, from $64.9 million in the comparable 2024 period.
• The DAZALS trial for dazucorilant in ALS did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R).
• The comparison between relacorilant and placebo for systolic blood pressure in the GRADIENT trial was not statistically significant, despite improvements in the relacorilant group.
• The company faces ongoing patent litigation regarding Korlym, with an adverse District Court ruling appealed to the Federal Circuit, and Teva having already launched a generic version.
• New antitrust litigation has been filed by Teva and Aetna, alleging violations of federal and state antitrust and unfair business practices laws.
• The Inflation Reduction Act of 2022 (IRA) is anticipated to limit Medicare revenue and materially reduce profits from 2026 onwards due to price negotiation and inflation rebates.
• The recently enacted One Big Beautiful Bill Act (OBBBA) of 2025 is expected to significantly reduce Medicaid funding, which could increase the cost of patient financial assistance programs.

Risks

• Failure to generate sufficient revenue from the sale of products would harm financial results and likely cause stock price to decline.
• The availability of generic versions of Korlym could adversely affect business, results of operations, and financial position.
• Public perception of mifepristone or legislation limiting or barring its distribution or use for termination of early pregnancy may limit the ability to sell current products.
• New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible to obtain acceptable prices or adequate insurance coverage and reimbursement for products.
• Vendors performing clinical trial activities may fail to perform duties or meet expected timelines, preventing or delaying approval of product candidates.
• Clinical drug development is lengthy, expensive, and often unsuccessful, with results of early studies and trials often not predictive of later trial results.
• Failure to obtain or maintain regulatory approvals for product candidates would prevent commercialization.
• Inability to secure, maintain, or effectively assert patent protection for proprietary selective cortisol modulators and for the use of products to treat hypercortisolism.
• The price of common stock fluctuates widely and is likely to continue to do so, with limited opportunities for investors to sell shares.
• Stock price may decline if performance does not meet public guidance, research analyst estimates, or other investor expectations.
• Actions by the federal government of the United States have created unprecedented legal, governmental, regulatory, and economic uncertainty and risks.
• Reliance on information technology means a breakdown or breach of systems or failure to protect confidential information could interrupt business and subject to liability.
• Changes in federal, state, and local tax laws may reduce net earnings.
• Research analysts may not continue to provide or initiate coverage of common stock or may issue negative reports.
• Any acquisition of shares through the stock repurchase program or pursuant to stock option exercises will reduce cash reserves.
• Anti-takeover provisions in the charter and bylaws and under Delaware law may make an acquisition or management change more expensive or difficult.
• Officers, directors, and principal stockholders, acting as a group, could significantly influence corporate actions.

Future Outlook

Research and development expenses are expected to be higher in 2025 than in 2024 as clinical programs advance and new clinical trials are initiated. Selling, general and administrative expenses are also expected to be higher in 2025 due to increased commercial and administrative activities supporting sales and marketing efforts. The Inflation Reduction Act of 2022 is anticipated to limit revenue from Medicare patients and may materially reduce profits in 2026 and beyond. The recently enacted One Big Beautiful Bill Act (OBBBA) of 2025 is expected to decrease current income taxes payable and deferred tax asset balances in the third and fourth quarters of 2025, primarily by allowing immediate expensing of domestic research and development activities, but will also significantly reduce Medicaid funding.

Management Comments

• We expect our research and development expense to be higher in 2025 than in 2024 as our clinical programs advance and we initiate new clinical trials.
• We expect our selling, general and administrative expense to be higher in 2025 than in 2024 due to increased commercial and administrative activities to support our increased sales and marketing efforts.
• Based on our current plans and expectations, we expect to fund our operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds, although we may choose to raise additional funds for other reasons.

Industry Context

The biopharmaceutical industry continues to focus on developing treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders. Corcept's advancements in hypercortisolism, ovarian cancer, ALS, and MASH align with this trend, targeting areas with significant unmet medical needs. The company faces competition in the hypercortisolism market from approved medications like Recordati-S.p.A.'s pasireotide and osilodrostat, and Xeris Biopharma Holdings, Inc.'s levoketoconazole, as well as off-label generic ketoconazole. The increasing regulatory scrutiny on drug pricing and reimbursement, exemplified by the Inflation Reduction Act, reflects a broader industry challenge impacting profitability and market access for pharmaceutical companies.

Comparison to Industry Standards

• In the hypercortisolism market, Corcept's Korlym and its authorized generic compete with Recordati-S.p.A.'s injectable somatostatin analogue pasireotide and cortisol synthesis inhibitor osilodrostat, and Xeris Biopharma Holdings, Inc.'s cortisol synthesis inhibitor levoketoconazole. Korlym's unique mechanism of action (glucocorticoid receptor modulation) differentiates it from these competitors, which primarily focus on cortisol synthesis inhibition or somatostatin analogue activity.
• Relacorilant's development for hypercortisolism aims to offer a differentiated profile compared to Korlym and other approved treatments by lacking affinity for the progesterone receptor and not prolonging the heart's QT interval, addressing known side effects in the current treatment landscape.
• For platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel is being developed against a backdrop where prior bevacizumab therapy is the approved standard of care. The positive PFS and OS benefits observed in ROSELLA and Phase 2 trials suggest a potential improvement over nab-paclitaxel monotherapy, which is a common chemotherapy agent in this setting.
• The ALS program with dazucorilant, while not meeting its primary functional endpoint, showed a significant survival benefit. This outcome is notable in a disease area where effective treatments are scarce, and survival benefits are highly valued, potentially positioning it differently from other ALS drug candidates that may focus solely on functional decline.

Legal Proceedings

• Teva Patent Litigation: Appeal ongoing in the United States Court of Appeals for the Federal Circuit regarding a District Court ruling that Teva's generic Korlym product does not infringe Corcept's patents. Oral argument was heard on July 7, 2025. Teva launched its generic product in January 2024.
• Teva Antitrust Litigation: Teva Pharmaceuticals USA, Inc. filed a complaint on June 13, 2024, in the Northern District of California, alleging federal and state antitrust and unfair business practices against Corcept and Optime Care, Inc. A First Amended Complaint was filed on September 13, 2024, and a motion to dismiss has been filed.
• Aetna Litigation: Several named plaintiffs filed a complaint on February 10, 2025, in Alameda County Superior Court (California) against Corcept, with allegations substantially similar to the Teva Antitrust Litigation. The case was removed to the United States District Court for the Northern District of California, and a hearing on the plaintiffs' motion to remand is scheduled for August 20, 2025.
• Melucci Litigation: A purported securities class action complaint, finalized a settlement in 2024 with a one-time payment of $14.0 million, which was fully reimbursed by insurers. This matter is closed.
• Shareholder Derivative Complaints (Williams, Jeweltex, Ritchie): Multiple purported shareholder derivative complaints alleging breach of fiduciary duty, violation of Section 14(a) of the Exchange Act, insider selling, misappropriation of insider information, and waste of corporate assets. The Williams and Jeweltex cases were consolidated and stayed pending the outcome of the Ritchie case in the Delaware Court of Chancery. The Ritchie case was dismissed on July 22, 2025. The United States District Court's response to this dismissal is pending.
• Records Subpoena: Received a records subpoena in November 2021 from the United States Attorney's Office for the District of New Jersey (NJ USAO) seeking information related to the sale and promotion of Korlym, relationships with healthcare professionals, and prior authorizations/reimbursement. The NJ USAO is investigating potential criminal or civil violations but does not currently consider Corcept a defendant. The company is cooperating with the investigation.

Stakeholder Impact

• Shareholders: Potential for stock price volatility due to mixed financial results, ongoing litigation outcomes, and future regulatory decisions. The aggressive stock repurchase program may support share price but also reduces cash reserves. Dilution from stock option exercises and restricted stock grants continues.
• Patients: Continued access to Korlym and its authorized generic for Cushing's syndrome. Potential for new treatment options with relacorilant for hypercortisolism and platinum-resistant ovarian cancer, and dazucorilant for ALS, if regulatory approvals are obtained. Patient support programs may be impacted by changes in government funding (e.g., OBBBA).
• Employees: Increased employee compensation expenses reflect ongoing investment in human capital. Stock-based compensation remains a significant component of overall compensation.
• Insurers/Payers: The Inflation Reduction Act and One Big Beautiful Bill Act are expected to significantly impact reimbursement rates and funding for Medicare and Medicaid, potentially leading to lower prices for products and increased costs for patient assistance programs.
• Suppliers/Vendors: Continued reliance on third-party vendors for manufacturing, clinical trials, and distribution, with potential for disruptions if vendors fail to perform or comply with regulations.

Next Steps

• Anticipate FDA decision on relacorilant NDA for endogenous hypercortisolism by the PDUFA target action date of December 30, 2025.
• Continue the MOMENTUM trial for hypercortisolism in patients with resistant hypertension, with a planned enrollment of 1,000 patients.
• Continue the open-label, long-term extension study for dazucorilant in ALS patients.
• Proceed with the Phase 2 BELLA trial of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer.
• Continue the Phase 2b MONARCH trial of miricorilant in patients with MASH.
• Evaluate next steps for cortisol modulation in combination with immunotherapies for other tumor types and earlier stages of cancer.
• Monitor the impact of the One Big Beautiful Bill Act (OBBBA) on current income taxes payable and deferred tax asset balances in Q3 and Q4 2025.
• Await the United States Court of Appeals for the Federal Circuit's opinion on the appeal of the Teva patent litigation ruling.
• Await the District Court's ruling on the motion to dismiss in the Teva Antitrust Litigation.
• Attend the federal court hearing on August 20, 2025, regarding the motion to remand the Aetna Litigation case back to state court.
• Monitor the United States District Court for the District of Delaware's response to the Delaware Court of Chancery's dismissal of the Joel B. Ritchie shareholder derivative complaint.

Key Dates

Recommendation

Corcept Therapeutics presents a mixed financial picture with strong revenue growth driven by volume, but a significant decline in net income and operating profit due to substantially increased expenses. The company's pipeline is robust, with two relacorilant NDAs submitted for hypercortisolism and ovarian cancer, representing major potential catalysts. The exploratory survival benefit in the ALS program is also noteworthy. However, the aggressive share repurchase program is depleting cash reserves, and the company faces multiple complex legal challenges (patent infringement, antitrust) with uncertain outcomes. Furthermore, new government regulations like the IRA and OBBBA are projected to negatively impact future profitability and Medicaid funding. Given the balance of promising clinical advancements against financial headwinds, cash burn, and significant legal/regulatory risks, a 'hold' recommendation is appropriate. Investors should await clarity on the relacorilant approvals and the resolution of key legal proceedings before making a more definitive investment decision.

Keywords

Biopharmaceutical, Cushing's syndrome, Hypercortisolism, Ovarian cancer, ALS, MASH, Relacorilant, Korlym, Dazucorilant, Miricorilant, FDA, NDA, Clinical trials, Drug development, SEC filing, 10-Q, Cortisol modulator, Oncology, Endocrinology, Metabolic disorders, Neuroscience, Patent litigation, Antitrust litigation, Stock repurchase, Revenue, Net income, Operating expenses